文献速递甲状腺疾病

TP53改变与晚期甲状腺癌患者对仑伐替尼反应不佳相关

TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究评估了TP53突变对晚期甲状腺癌患者仑伐替尼疗效的影响,发现TP53突变与仑伐替尼反应不佳显著相关(P = .005),且TP53突变患者无进展生存期(P < .0001)和总生存率(P = .0007)更短。在甲状腺癌细胞系中,p53改变者对仑伐替尼敏感性低或无,而TP53野生型者显示不同程度的敏感性。

要点

  • TP53突变与晚期甲状腺癌患者对仑伐替尼反应不佳显著相关(P = .005)。
  • TP53突变患者无进展生存期(P < .0001)和总生存率(P = .0007)更短。
  • p53表达改变患者无进展生存期和总生存期更短(P = .0001和P = .0056)。

核心结论

  • 在晚期甲状腺癌中,TP53改变是仑伐替尼治疗反应不佳的预测因素,并与更差的无进展生存率和总生存率相关。
  • 作者认为,在开始多激酶抑制剂治疗前,可将TP53突变/p53表达评估纳入患者/肿瘤特征分析。

研究设计与样本

  • 研究分析了30例接受仑伐替尼治疗的甲状腺癌患者的肿瘤组织分子谱(包括TP53突变),并通过免疫组化检测p53状态,数据与临床病理特征及肿瘤反应进行比较。
  • 在TP53缺陷和TP53正常的甲状腺癌细胞系中评估了对仑伐替尼的反应。
  • 数据在验证队列中得到确认。

主要发现

  • TP53突变与仑伐替尼反应不佳显著相关(P = .005)。
  • TP53突变患者无进展生存期更短(P < .0001),总生存率更短(P = .0007)。
  • 核p53蛋白表达改变的患者无进展生存期和总生存期更短(分别为P = .0001和P = .0056)。
  • 甲状腺癌细胞系中,p53改变者敏感性低或无,而TP53野生型者显示不同程度的敏感性,主要由于G1期肿瘤细胞数量增加,与仑伐替尼的细胞静止效应一致。

临床怎么用

  • 作者认为,在开始多激酶抑制剂治疗前,可将TP53突变/p53表达评估纳入患者/肿瘤特征分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC). OBJECTIVE: We evaluated the effect of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in vitro models. METHODS: We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines. RESULTS: TP53 mutations significantly correlated with a poor response to LEN (P = .005). TP53-mutated patients had a shorter progression-free survival (PFS) (P < .0001) and overall survival (OS) rates (P = .0007). Accordingly, patients harboring altered nuclear p53 protein expression had shorter PFS and OS (P = .0001 and P = .0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those with TP53 wild-type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN. CONCLUSION: We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cirello V, Colombo C, Tosi D, et al. TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39891677. doi:10.1210/clinem/dgaf056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。